{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:43:37Z","timestamp":1771065817330,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10758"],"award-info":[{"award-number":["10758"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,9,26]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CHEK2<\/jats:italic>\n                      c.1100delC is associated with an increased breast cancer risk in women. While this variant is prevalent in the Netherlands (1% in the general population), knowledge of aetiology and prognosis of breast cancer and other tumours in\n                      <jats:italic>CHEK2<\/jats:italic>\n                      c.1100delC carriers is lacking. The nationwide HEreditary Breast and Ovarian cancer study the Netherlands (Hebon) cohort aims to answer study questions in families with an increased risk of breast cancer and ovarian cancer. While initially focusing on\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      -variant families, Hebon gradually expanded to include pathogenic variants in other genes associated with breast and\/or ovarian cancer over time. This provides an excellent setting to establish a cohort to ultimately study the impact of\n                      <jats:italic>CHEK2<\/jats:italic>\n                      c.1100delC on cancer risk prediction and surveillance, breast cancer treatment and prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      We invited all heterozygous and homozygous\n                      <jats:italic>CHEK2<\/jats:italic>\n                      c.1100delC indexes and tested female relatives. 1802 women were included, of whom 1374 were heterozygotes and 938 were breast cancer cases. Pedigrees were collected from all clinical genetic departments. Furthermore, participants completed a detailed questionnaire on hormonal and lifestyle factors, family history, cancer diagnosis and treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>Mean age at study inclusion was 53 years. Linkage with the Netherlands Cancer Registry showed a younger age at diagnosis in homozygotes (mean age 41.7 years) and heterozygotes (47.9 years) than non-carriers (51.2 years). Furthermore, carriers were more often diagnosed with grade 2, oestrogen receptor-positive breast cancer and more often developed contralateral breast cancer than non-carriers. Most women consumed alcohol regularly and about half never smoked.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>Further data linkages with the Netherlands Cancer Registry will allow prospective follow-up and breast cancer risk assessment in unaffected women at the time of genetic testing, risk of contralateral breast cancer and survival in patients with breast cancer. Also, linkage with the nationwide network and registry of histopathology and cytopathology in The Netherlands (PALGA) allows us to retrieve tumour samples to study tumourigenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-086688","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T11:50:37Z","timestamp":1728474637000},"page":"e086688","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Cohort profile: a nationwide study in Dutch\n                    <i>CHEK2<\/i>\n                    c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands \u2013 Hebon-CHEK2"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1826-5344","authenticated-orcid":false,"given":"Maartje A.C.","family":"Schreurs","sequence":"first","affiliation":[{"name":"Erasmus MC Cancer Centre, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel A","family":"Adank","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Hollestelle","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"de Groot","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise J","family":"Stommel-Jenner","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christi J.","family":"Van Asperen","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margreet G.E.M.","family":"Ausems","sequence":"additional","affiliation":[{"name":"Medical Genetics, UMC, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieke P V","family":"Berger","sequence":"additional","affiliation":[{"name":"UMCG, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinus J","family":"Blok","sequence":"additional","affiliation":[{"name":"Maastricht UMC+, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaartje","family":"van Engelen","sequence":"additional","affiliation":[{"name":"Amsterdam UMC Locatie AMC, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans B L","family":"Hogervorst","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willemina","family":"Geurts-Giele","sequence":"additional","affiliation":[{"name":"Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan J P","family":"Gille","sequence":"additional","affiliation":[{"name":"Amsterdam UMC Locatie AMC, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijke R","family":"Wevers","sequence":"additional","affiliation":[{"name":"Radboudumc, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjanka K","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[{"name":"Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"2025120519044120000_14.10.e086688.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025120519044120000_14.10.e086688.2","unstructured":"Netherlands Cancer Registry . Borstkanker in Nederland, kerncijfers uit de Nederlandse Kankerregistratie. 2024. Available: www.iknl.nl\/borstkankercijfers"},{"key":"2025120519044120000_14.10.e086688.3","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/747318","article-title":"Hereditary breast cancer: the era of new susceptibility genes","volume":"2013","author":"Apostolou","year":"2013","journal-title":"Biomed Res Int"},{"key":"2025120519044120000_14.10.e086688.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.5844"},{"key":"2025120519044120000_14.10.e086688.5","article-title":"CHEK2-mutatie in Nederlandse borstkankerfamilies: uitbreiding van de genetische diagnostiek op borstkanker","volume":"159","author":"Adank","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2025120519044120000_14.10.e086688.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2004.03.033"},{"key":"2025120519044120000_14.10.e086688.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00110-7"},{"key":"2025120519044120000_14.10.e086688.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.01.009"},{"key":"2025120519044120000_14.10.e086688.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.0778"},{"key":"2025120519044120000_14.10.e086688.10","unstructured":"Stichting Opsporting Erfelijke Tumoren . CHEK2-geassocieerd mammacarcinoom VKGN - STOET: 21. 2023 Available: https:\/\/vkgn.stoet.nl\/index.php?article_id=23"},{"key":"2025120519044120000_14.10.e086688.11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40291-018-0344-x","article-title":"Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis","volume":"22","author":"Liang","year":"2018","journal-title":"Mol Diagn Ther"},{"key":"2025120519044120000_14.10.e086688.12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12885-017-3631-8","article-title":"CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population","volume":"17","author":"Hallamies","year":"2017","journal-title":"BMC Cancer"},{"key":"2025120519044120000_14.10.e086688.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00580-017-2455-x"},{"key":"2025120519044120000_14.10.e086688.14","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.147"},{"key":"2025120519044120000_14.10.e086688.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.5160"},{"key":"2025120519044120000_14.10.e086688.16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.306"},{"key":"2025120519044120000_14.10.e086688.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7336"},{"key":"2025120519044120000_14.10.e086688.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.3024"},{"key":"2025120519044120000_14.10.e086688.19","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.019737"},{"key":"2025120519044120000_14.10.e086688.20","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000010697.49896.03"},{"key":"2025120519044120000_14.10.e086688.21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604228"},{"key":"2025120519044120000_14.10.e086688.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01239"},{"key":"2025120519044120000_14.10.e086688.23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-2865-2","article-title":"Survival from breast cancer in patients with CHEK2 mutations","volume":"144","author":"Huzarski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2025120519044120000_14.10.e086688.24","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"key":"2025120519044120000_14.10.e086688.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0476-0"},{"key":"2025120519044120000_14.10.e086688.26","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2011-100380"},{"key":"2025120519044120000_14.10.e086688.27","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2013.85"},{"key":"2025120519044120000_14.10.e086688.28","doi-asserted-by":"publisher","DOI":"10.1086\/421251"},{"key":"2025120519044120000_14.10.e086688.29","first-page":"1539","article-title":"Risk of HER2-positive breast cancer among germline CHEK2 mutation carriers with breast cancer","volume":"34","author":"Ramamurthy","year":"2016","journal-title":"J C O"},{"key":"2025120519044120000_14.10.e086688.30","doi-asserted-by":"crossref","first-page":"101171","DOI":"10.1016\/j.gim.2024.101171","article-title":"Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families","volume":"26","author":"Schreurs","year":"2024","journal-title":"Genet Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-086688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:04:52Z","timestamp":1764990292000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-086688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,9]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/bmjopen-2024-086688"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-086688","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}